| Document |
Document Title |
|
WO/2023/236797A1 |
Disclosed in the present invention are a hangtaimycin derivative, a preparation method therefor, and the use thereof. The hangtaimycin derivative is prepared by performing fermentation in an SFMR culture medium by using Streptomyces spec...
|
|
WO/2023/240203A1 |
Disclosed herein are patches, methods, devices, and systems for delivering a non-aggregating peptide, such as alcadein and its fragments, into a subject. In some aspects, the patch includes a backing, a matrix comprising a non-aggregatin...
|
|
WO/2023/240171A1 |
Aspects of the disclosure provides composition and methods for treating a subject having a blood loss condition, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).
|
|
WO/2023/240137A1 |
The present disclosure provides Cas protein variants comprising one or more amino acid substitutions relative to wild-type Casl4al. Fusion proteins comprising the Cas protein variants described herein are also provided by the present dis...
|
|
WO/2022/236107A9 |
Provided herein are compositions and methods of reducing inflammation in a subject comprising administering to the subject a pharmaceutically effective amount of a mast cell desensitizing composition.
|
|
WO/2023/239937A1 |
This invention relates to methods and compositions directed to mobilizing a cell in a subject by blocking CXCR4, a beta-adrenergic receptor, a GPCR, or any combination thereof. In some embodiments, the cell is a stem cell. In some embodi...
|
|
WO/2023/240109A1 |
The invention provides multispecific molecules that are capable of binding to an antigen-specific T cell receptor (TCR) expressed on a surface of a cell, said multispecific molecules comprising a first molecule and a second molecule, whe...
|
|
WO/2023/240120A2 |
Provided herein are engineered T cell receptor (TCR) proteins, nucleic acids, vectors, host cells, methods of treating atherosclerosis-related autoimmune disease, and chimeric antigen receptor expressing T cell (CAR-T) comprising a beta ...
|
|
WO/2023/238985A1 |
The present invention relates to a hyaluronidase polypeptide and a use thereof.
|
|
WO/2023/240062A1 |
Provided herein, inter alia, are melanopsin variants that demonstrate greater amplitude/conductance and/or faster off kinetics than the amplitude/conductance and/or the off kinetics of the wild type human melanopsin. Also provided are re...
|
|
WO/2023/235970A1 |
The present disclosure provides compounds with increased metabolic stability for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection, such as rhinovirus, coxsackievirus, norovirus and coronavirus. Aspects of th...
|
|
WO/2023/240027A1 |
Provided herein is a particle delivery system (PDS) comprising components selected from: (a) a fusion protein comprising one or more Mononegavirales structural proteins and a heterologous protein; (b) one or more therapeutic payloads; an...
|
|
WO/2023/238955A1 |
The present invention pertains to a method for controlling a membrane potential-dependent ion channel (VGSC or the like) through a type I taste receptor present in a nerve cell or the like. In the present invention, it has been found t...
|
|
WO/2023/239678A1 |
Collagen devices and methods of treating cancer in a patient. Such methods include the step of introducing a collagen device having a DDR1 peptide into the patient, whereby the DDR1 peptide is delivered to the cancer. Other such methods ...
|
|
WO/2023/236700A1 |
The present invention provides preparation of a cordyceps sinensis mycelium Cs4 polysaccharide protein functionalized nano-selenium hydrosol, and anti-cancer use thereof.
|
|
WO/2023/239229A1 |
Provided are a composition for stabilizing botulinum neurotoxin, a botulinum neurotoxin formulation containing same, and a polypeptide for use therein.
|
|
WO/2023/240270A2 |
The present disclosure is directed to compounds and compositions for treating PSP such as, for example, therapeutically effective amount of a saxiphilin. This abstract is intended as a scanning tool for purposes of searching in the parti...
|
|
WO/2023/236864A1 |
Provided in the present invention are a BAF155 mutant gene and the pharmaceutical use thereof. Provided in the present invention are a BAF155 mutant or an active fragment thereof. Compared with wild-type BAF155, the BAF155 mutant or the ...
|
|
WO/2023/239551A1 |
Provided herein are compositions containing guest/host inclusion complexes. In particular, each complex includes S-nitrosoglutathione (GSNO) as the guest and substituted or unsubstituted cyclodextrin as the host, such as alpha cyclodextr...
|
|
WO/2023/235938A1 |
Drug delivery systems are needed to assist in improving the therapeutic characteristics of pharmaceutical agents. Provided is a dry composition, comprising a polysaccharide, such as inulin, and lipid droplets, wherein the lipid droplets ...
|
|
WO/2023/240215A1 |
Provided herein are compositions and methods for the delivery of prosaposin and saposins within the tumor microenvironment in order to enhance anti-tumor immunity.
|
|
WO/2023/240031A1 |
The present invention provides compositions and methods for treating Postural orthostatic tachycardia syndrome (POTS) In some embodiments, the POTS is associated with hypermobility spectrum disorders/hypermobile Ehlers-Danlos syndrome (H...
|
|
WO/2023/236345A1 |
The present application relates to a genetic engineering drug for treating inflammatory arthritis and a preparation method therefor. Specifically, the present application provides a use of an A20 protein or a functional active fragment t...
|
|
WO/2023/235964A1 |
A protease-resistant ADAMTS13 mutant protein or nucleic acid encoding the ADAMTS13 mutant protein is provided. The ADAMTS13 mutant protein comprises a mammalian ADAMTS13 protein in which one or more protease cleavage sites within the pro...
|
|
WO/2023/239925A1 |
Provided herein arc compounds of Formula (I- A), (I-B), or (I-C), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically enriched forms, prodrugs, or mixtures thereof, a...
|
|
WO/2023/240228A1 |
Combination therapies comprising a SIRPaFc fusion protein and an anti-CD19 agent are provided. The combination therapies can optionally further include an E3 ubiquitin ligase modulator.
|
|
WO/2023/237733A1 |
The invention relates to the use of at least one molecule selected from among an annelid globin, an annelid globin protomer and an annelid extracellular hemoglobin for the treatment of Fuchs' disease.
|
|
WO/2023/237731A1 |
The present invention relates to a functional N-terminal truncated GDE polypeptide for the treatment of glycogen storage disease III.
|
|
WO/2023/238916A1 |
The present invention addresses the problem of providing hollow spherical particles that have superior safety and can be produced more easily. This problem is solved by hollow spherical particles which are self-assembled bodies of a lign...
|
|
WO/2023/240220A1 |
This invention relates to viral vectors for delivery of N-sulfoglucosamine sulfohydrolase (SGSH) to a subject. In some aspects, the SGSH sequence is optimized for expression in human cells. The invention further relates to methods of usi...
|
|
WO/2023/240147A1 |
Disclosed herein are engineered iPSCs and cells derived therefrom that express CD16 variants and NKG2D. Also, the engineered iPSCs and cells derived therefrom can express a chimeric antigen receptor. Additionally, provided herein are pol...
|
|
WO/2023/235991A1 |
Provided herein are formulations for spray freeze drying to encapsulate active ingredients, methods of preparing a composition of spray freeze dried micro-particles from the formulations described herein, and micro-particle compositions....
|
|
WO/2023/239228A1 |
Provided are a fusion protein comprising an anti-TIGIT antibody binding specifically to TIGIT or an antigen-binding fragment thereof, interleukin-15 (IL-15), and an interleukin-15 receptor alpha (IL-15Rα) sushi domain, and medicinal use...
|
|
WO/2023/237774A1 |
The present invention relates to a fusion protein that provides for maintenance of regulatory T-cells that are polyclonal, e.g. natural isolated antigen-specific Treg cells, and/or Treg cells generated by introduction of a nucleic acid c...
|
|
WO/2023/236954A1 |
The present invention relates to a PD-1 variant and the use thereof. Specifically, the PD-1 variant of the present invention can bind to PD-L1 with high affinity, but does not bind to one or more anti-PD-1 monoclonal antibodies, and pref...
|
|
WO/2023/239213A1 |
An inflammatory cell-specific drug delivery system (CDC fusion protein) according to the present invention, which is based on a fusion protein of ubiquitin protein and caspase-1 recognition sequence, does not function in normal cells as ...
|
|
WO/2023/238127A1 |
The present invention provides cyclic peptides, as well as methods of using the same, such as for ameliorating or treating a K63Ub-related disease in a subject in need thereof.
|
|
WO/2023/236863A1 |
The present invention provides a deacetylation modified BAF155 protein and a pharmaceutical use thereof. The present invention provides a deacetylation modified BAF155 protein or an active fragment thereof. Compared with a wild-type BAF1...
|
|
WO/2023/239069A1 |
The present application relates to a peptide exhibiting muscle loss prevention and muscle mass promotion activities, and use thereof, and provides: a peptide having an amino acid sequence of SEQ ID NO: 1; a pharmaceutical composition for...
|
|
WO/2023/236878A1 |
The present application relates to a truncated IgA protease, a fusion protein comprising the truncated IgA protease (e.g., a fusion protein comprising the truncated IgA protease and an Fc), and use thereof in treating an IgA deposition d...
|
|
WO/2022/241010A9 |
Compositions and methods for reducing viral load in the oral cavity, particularly Coronavirus such as SARS-CoV-2 and Influenza viral loads are disclosed. Also disclosed are compositions and methods for reducing bacterial or fungal loads ...
|
|
WO/2023/233095A1 |
The invention relates to ESM-1 (Endothelial cell Specific Molecule) or a pharmaceutical composition containing it for use in a method for treating or preventing acute respiratory distress syndrome (ARDS) in a patient.
|
|
WO/2023/231402A1 |
Provided is use of UbV.E4B protein in the preparation of a medicament for promoting central nervous regeneration. The UbV.E4B protein promotes the axonal regeneration of a central nervous system by selectively inhibiting a Ube4b ubiquiti...
|
|
WO/2023/235848A1 |
The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2Rα moiety and a protease-cleavable linker, configured such that the IL2Rα moiety is released from the IL2 moiety upon the action of a pr...
|
|
WO/2023/232083A1 |
The present invention belongs to the field of biomedicine, and relates to a beta 2-microglobulin blocking peptide, and a pharmaceutical composition and the use thereof. In particular, the present invention relates to an isolated polypept...
|
|
WO/2023/235360A1 |
This disclosure provides methods for using a particular class of apelin receptor modulators to reduce blood-brain barrier (BBB) permeability in a subject in need thereof, and in particular methods of treatment for a variety of disorders,...
|
|
WO/2023/232111A1 |
The present disclosure provides a MAGE-A1-specific TCR and use thereof, and specifically relates to a TCR modified to improve binding affinity, a nucleic acid encoding same, a vector comprising the nucleic acid of the present invention, ...
|
|
WO/2023/235292A1 |
The disclosure provides a device for sustained release of a therapeutic agent, comprising a capsule configured for implantation and having a reservoir; a nanoporous membrane with a plurality of pores; the therapeutic agent disposed withi...
|
|
WO/2023/233791A1 |
Provided are: an integrin activator that contains a substance that inhibits binding between a fibronectin and an immune inhibitory receptor LILRB4 as an active ingredient; and a therapeutic agent that contains a substance that inhibits b...
|
|
WO/2023/234410A1 |
The present invention addresses the problem of providing: an inhibitory agent for myocardial cell death; and a prophylactic or therapeutic agent for myocardial disorders or heart failure. The problem is solved by an inhibitory agent for ...
|
